Hormonal
GLP-1 receptor agonists (GLP-1RAs) effectively manage type 2 diabetes and obesity by mimicking endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, and promote satiety through delayed gastric emptying and hypothalamic signaling.
GLP-1 receptor agonists are a proven treatment for Type 2 Diabetes and obesity. They work by mimicking a natural hormone to help your pancreas release insulin when needed, stop the release of sugar-storing hormones, and make you feel full faster. This leads to better blood sugar control and weight loss. While they are effective, they require injections, which can be a barrier for some patients.
GLP-1 plays a crucial role in maintaining stable blood sugar levels by promoting glucose-dependent insulin production from pancreatic beta cells and reducing glucagon output from pancreatic alpha cells... GLP-1, beyond its role in glucose homeostasis, also controls hunger and promotes fullness by slowing stomach emptying and acting on hypothalamic neurons... These drugs have proven effective in managing chronic illnesses such as type 2 diabetes (T2D) and obesity, enhancing glycemic control, promoting weight loss, and reducing cardiovascular issues.
Why this rating
The paper is a review citing multiple clinical trials and in vivo/in vitro studies, but lacks a single primary clinical trial with specific patient data.
Source
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
Tohada M. AL‐Noshokaty et al. · Toxicology Reports · 2025
DOI 10.1016/j.toxrep.2025.101895
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →